Why Is TREVI THERAPEUTICS I (TRVI) Stock Down Today?

Trevi Therapeutics Inc. shares fell 12.06% to $16.77 on Monday amid a sharp intraday decline. Despite a price target increase from H.C. Wainwright to $24, the stock struggled to hold early gains and closed significantly lower. The session was marked by high volatility and strong volume.

What Happened

The stock opened at $19.11 and reached an intraday high of $19.39 shortly after 9:25 AM ET. However, it quickly lost momentum and drifted lower throughout the session. By 3:55 PM ET, the stock hit a session low of $16.62 before closing at $16.77. The move came despite two separate price target upgrades from analysts. H.C. Wainwright raised its price target to $24, and B. Riley Securities increased its target to $31. These upgrades did not prevent the stock from closing nearly 12% below its opening price. The company remains unprofitable with a trailing twelve-month earnings per share of -0.32 and a market capitalization of $2.7 billion.

What The Data Shows

The stock traded 2.2 million shares during the session, which is 1.2 times the 3-month daily average. The price action reflects a volatile session, with the stock falling from its morning high to a near 52-week low. The 52-week range for TRVI is $6.55 to $20.22, and the current price is near the lower end of that range. The stock’s beta of 1.00 indicates it is moving in line with the broader market, but its performance today was driven more by internal volatility than external market conditions.

What To Watch

Trevi Therapeutics has no upcoming earnings date listed. Investors should monitor the breadth of analyst coverage and any further price target changes from key firms like H.C. Wainwright and B. Riley Securities.